Streptococcal inhibitor of complement promotes innate immune resistance phenotypes of invasive M1T1 group A Streptococcus.
Pence. Morgan A MA; Rooijakkers. Suzan H M SH; Cogen. Anna L AL; Cole. Jason N JN; Hollands. Andrew A; Gallo. Richard L RL; Nizet. Victor V
Key Findings
- SIC production spikes when the bacteria acquire covS mutations, making them more invasive
- SIC binds both human and mouse LL‑37, protecting the bacteria from this peptide
- Removing the sic gene makes the bacteria weaker in blood, serum, and mouse infection models
Practical Outcomes
- LL‑37 may be less effective against group A strep that produce SIC, so simply taking LL‑37 isn’t a guaranteed defense. Strategies that inhibit SIC or use modified LL‑37 variants could improve outcomes, and users should be aware of bacterial resistance mechanisms when considering LL‑37‑based interventions.
Summary
The study shows that a protein made by dangerous strep bacteria (SIC) can grab and neutralize the human antimicrobial peptide LL‑37, helping the bacteria survive in blood and cause infection. This means LL‑37’s natural defense role can be blocked by certain bacterial strains.
Abstract
Streptococcal inhibitor of complement (SIC) is a highly polymorphic extracellular protein and putative virulence factor secreted by M1 and M57 strains of group A Streptococcus (GAS). The sic gene is highly upregulated in invasive M1T1 GAS isolates following selection of mutations in the covR/S regulatory locus in vivo. Previous work has shown that SIC (allelic form 1.01) binds to and inactivates complement C5b67 and human cathelicidin LL-37. We examined the contribution of SIC to innate immune resistance phenotypes of GAS in the intact organism, using (1) targeted deletion of sic in wild-type and animal-passaged (covS mutant) M1T1 GAS harboring the sic 1.84 allele and (2) heterologous expression of sic in M49 GAS, which does not possess the sic genein its genome. We find that M1T1 SIC production is strongly upregulated upon covS mutation but that the sic gene is not required for generation and selection of covS mutants in vivo. SIC 1.84 bound both human and murine cathelicidins and was necessary and sufficient to promote covS mutant M1T1 GAS resistance to LL-37, growth in human whole blood and virulence in a murine model of systemic infection. Finally, the sic knockout mutant M1T1 GAS strain was deficient in growth in human serum and intracellular macrophage survival. We conclude that SIC contributes to M1T1 GAS immune resistance and virulence phenotypes.
Study Information
pubmed
2010
2010-09-01T00:00:00.000Z
10.1159/000317672
55
31